{"id":"sjp-0132","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital mycotic infections"},{"rate":"null","effect":"Increased risk of urinary tract infections"},{"rate":"null","effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL3927903","moleculeType":"Small molecule","molecularWeight":"407.93"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"SJP-0132 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and increasing glucose excretion in the urine.","oneSentence":"SJP-0132 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:34:51.755Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06717152","phase":"PHASE3","title":"Efficacy and Safety of SJP-0132 Eye Drops in Chinese Patients With Dry Eye Disease","status":"COMPLETED","sponsor":"Senju Pharmaceutical Science & Technology (Beijing) Co., Ltd.","startDate":"2024-12-30","conditions":"Dry Eye","enrollment":427},{"nctId":"NCT04139122","phase":"PHASE1, PHASE2","title":"Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Senju Pharmaceutical Co., Ltd.","startDate":"2019-10-05","conditions":"Dry Eye Disease, Dry Eye Syndrome","enrollment":89}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SJP-0132","genericName":"SJP-0132","companyName":"Senju Pharmaceutical Co., Ltd.","companyId":"senju-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SJP-0132 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}